The U.S. Supreme Court on April 17 rejected Novartis’ bid to resurrect a case concerning a key patent for Gilenya, its blockbuster multiple sclerosis drug, according to Bloomberg Law. A U.S. federal appeals court in June 2022 ruled the patent invalid, siding with Chinese generic drugmaker HEC Pharma. Gilenya was Novartis’ fourth best-selling drug in 2022, bringing in 2.0 billion in worldwide sales, but Evaluate Pharma projects the drug will not crack the top 10 for 2023. For the treatment of multiple sclerosis, 85% of all insured lives have covered or better access to Gilenya under the pharmacy benefit. About 9% of insured lives have preferred access to Gilenya without utilization management restrictions.